Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Chronic Pancreatitis I: Introduction01:25

Chronic Pancreatitis I: Introduction

Chronic pancreatitis is a long-standing, relapsing inflammation of the pancreas, characterized by irreversible damage to the gland. It results in progressive destruction of the pancreatic parenchyma, fibrosis, and eventual loss of both exocrine and endocrine function. The disease may evolve gradually after multiple episodes of acute pancreatitis or develop independently.EtiologyChronic pancreatitis can arise from a variety of causes:Alcohol use is the leading cause, accounting for 70–80% of...
Chronic Pancreatitis I: Introduction01:24

Chronic Pancreatitis I: Introduction

The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

COVID-19 and chronic liver disease: results from the 1219 patients French registry.

Scientific reports·2025
Same author

RNA editing blood biomarkers for predicting mood alterations in HCV patients.

Journal of neurovirology·2019
Same author

Efficacy, safety and patient-reported outcomes of ledipasvir/sofosbuvir in NS3/4A protease inhibitor-experienced individuals with hepatitis C virus genotype 1 and HIV coinfection with and without cirrhosis (ANRS HC31 SOFTRIH study).

HIV medicine·2017
Same author

The negative impact of HBV/HCV coinfection on cirrhosis and its consequences.

Alimentary pharmacology & therapeutics·2017
Same author

Proton pump inhibitors protect mice from acute systemic inflammation and induce long-term cross-tolerance.

Cell death & disease·2016
Same author

Open-label study of faldaprevir plus peginterferon and ribavirin in hepatitis C virus genotype 1-infected patients who failed placebo plus peginterferon and ribavirin.

Journal of viral hepatitis·2015

Related Experiment Video

Updated: Jul 3, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

[New perspective in chronic hepatitis B therapy].

M Bourlière1, P Castellani

  • 1Service d'Hépato-Gastroentérologie, Hôpital saint joseph, 26, bd de Louvain, 13008 Marseille, France.

Gastroenterologie Clinique Et Biologique
|July 30, 2008
PubMed
Summary

New treatments for chronic hepatitis B, including antiviral drugs and immunotherapies, show promise. Combining therapies may improve outcomes, but further research is needed to identify optimal patient candidates for these hepatitis B virus (HBV) treatments.

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Related Experiment Videos

Last Updated: Jul 3, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Area of Science:

  • Hepatology and Virology
  • Immunology and Immunotherapy
  • Pharmacology and Drug Development

Context:

  • Chronic hepatitis B (HBV) infection remains a significant global health challenge.
  • Current antiviral therapies effectively suppress HBV replication but rarely achieve viral elimination.
  • There is a need for novel therapeutic strategies to achieve a functional cure for chronic hepatitis B.

Purpose:

  • To review current and emerging therapeutic options for chronic hepatitis B.
  • To evaluate the potential of antiviral drugs, therapeutic vaccines, and immunotherapies.
  • To explore combination strategies for enhanced HBV control and viral clearance.

Summary:

  • Antiviral drugs like tenofovir disoproxil fumarate and clevudine suppress HBV viral load with low short-term resistance.
  • Immunotherapies and therapeutic vaccines aim to induce HBV-specific T-cell responses for viral control and elimination of infected cells.
  • Combination therapy of antiviral drugs and therapeutic vaccines presents a promising approach for chronic hepatitis B treatment.

Impact:

  • Understanding HBV-specific T-cell responses is crucial for selecting patients who will benefit from immunotherapy.
  • Further large-scale studies are required to optimize combination therapies for chronic hepatitis B.
  • These advancements could lead to improved functional cure rates and long-term management of hepatitis B.